Ikke desto mindre tyder visse kliniske data på, at den generelle sandsynlighed for ugunstige hændelser stiger, hvis patienterne samtidig udsættes for tasonermin og interferon- gamma.
Clinical data however indicate that the overall incidence of adverse events is increased if patients are simultaneously exposed to tasonermin and interferon-gamma.